Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07392723 · ClinicalTrials.gov registry record · Phase 2
ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults
A Phase 2 study of Alzheimer Disease and Cognitive Dysfunction, sponsored by Michal Schnaider Beeri, Ph.D..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07392723 is a Phase 2 study of Alzheimer Disease and Cognitive Dysfunction that is actively recruiting participants, run by Michal Schnaider Beeri, Ph.D.. The registered enrollment target is 20 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07392723, a Phase 2 study of Alzheimer Disease and Cognitive Dysfunction, is actively recruiting participants, sponsored by Michal Schnaider Beeri, Ph.D..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized, double-blind, placebo-controlled pilot trial will evaluate the effects of alpha-linolenic acid (ALA) supplementation on cognitive function, blood-brain barrier integrity, and brain vascular health in older adults with mild cognitive impairment and APOE4 genotype. By targeting the endogenous synthesis of docosahexaenoic acid (DHA) through ALA supplementation, the investigators aim to overcome the limitations of direct DHA supplementation, particularly in APOE4 carriers who exhibit low brain DHA levels and impaired blood-brain barrier function. This innovative approach offers a safe, cost-effective, and easily implementable therapeutic strategy for older adults at high risk for Alzheimer's dementia, especially APOE4 carriers, addressing a critical need given the limited cognitive benefits and significant adverse events of current amyloid-clearing drugs in this population.
Conditions Studied
Interventions
- DRUG Alpha-Linolenic Acid (2.6 g/day)
- DIETARY_SUPPLEMENT Placebo Control Group
Study Locations (1)
New Jersey
- Rutgers - Institute for Health - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-01-12 |
| Est. Completion | 2027-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07392723
The ClinicalTrials.gov registry entry for NCT07392723 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The listed sponsor is Michal Schnaider Beeri, Ph.D., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Alpha-Linolenic Acid (2.6 g/day) is the first listed.
NCT07392723 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT07392723 about?
NCT07392723 is a clinical study titled "ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults". This randomized, double-blind, placebo-controlled pilot trial will evaluate the effects of alpha-linolenic acid (ALA) supplementation on cognitive function, blood-brain barrier integrity, and brain vascular health in older adults with mild cognitive impairment and APOE4 genotype. By targeting the en...
What is the current status of trial NCT07392723?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-01-12. Estimated completion is 2027-10.
What conditions does trial NCT07392723 study?
This clinical trial studies the following conditions: Alzheimer Disease, Cognitive Dysfunction, Brain Aging, Blood-Brain Barrier, Apolipoprotein E, Deficiency or Defect of.
What interventions are being tested in trial NCT07392723?
The interventions under investigation include: Alpha-Linolenic Acid (2.6 g/day) (DRUG), Placebo Control Group (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07392723?
This trial is sponsored by Michal Schnaider Beeri, Ph.D., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07392723 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
RECRUITING · Phase 2
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
RECRUITING · Phase 2
-
Sleep Trial to Prevent Alzheimer's Disease
RECRUITING · Phase 2
-
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
RECRUITING · Phase 2
-
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.